<DOC>
	<DOC>NCT02578043</DOC>
	<brief_summary>The objectives of this study are to evaluate the therapeutic equivalence and safety.</brief_summary>
	<brief_title>A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris</brief_title>
	<detailed_description>The objectives of this study are to evaluate the therapeutic equivalence and safety of the test product Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to the reference product Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of these test and reference products over the placebo control.</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris. Must have a minimum ≥ 25 noninflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions at baseline on the face. Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment. Female subjects who are pregnant, nursing or planning to become pregnant during study participation. A history or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibioticassociated colitis. A history of hypersensitivity or allergy to clindamycin, benzoyl peroxide and/or any of the study medication ingredients and its excipients.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>